EN DE
Watch Applied BioCode for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Applied BioCode (6598) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Applied BioCode stock TWD 4.76, price TWD 27.00, that is 82.4% below the price, quality 54 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN KYG0488D1051

AB Applied BioCode logo Thin data Nov 9, 2026

Applied BioCode

6598 · TW
Solid, but very expensive

Our calculation puts a fair price 82% below what the stock costs today.

Low debt
Revenue last quarter +81% vs. a year ago.
Quality 54/100
Expensive Growth (revenue 5y +9.7 %/yr in TWD)
Mixed vs. peers (4/10)
Fair value 4.76 TWD · Strongly overvalued
Loss-making · -7.3% net margin (TTM)
Negative free cash flow
Narrow moat 23/100
Thin data
Watch Applied BioCode for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

56.80 TWD 17.45 TWD Fair Value 4.76 TWD Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

60‑month range 17.45 TWD – 56.80 TWD · fair‑value band 3.14 TWD – 5.94 TWD · the 27.00 TWD price screens above the 4.76 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Applied BioCode in your weekly email

Every Wednesday you see whether Applied BioCode is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California.

Show moreShow less

Its products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the detection steps, PCR amplification, and hybridization and target capture; and the BioCode 2500 analyzer, a system that reads each barcode and quantifies the BMB target using the fluorescence signal intensity.

The company develops assays, such as BioCode SARS-CoV-2 Assay, an assay for the detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs; and CoV-2 Flu Assay for detection of RNA and various Influenza, as well as offers gastrointestinal and respiratory pathogen panel related products.

In addition, it provides BioCode Fungal Panel, a multiplexed deoxyribonucleic acid (DNA) amplification test; and BioCode STI + Resistance Panel (RUO), a multiplex nucleic acid amplification test. Further, the company offers barcoded magnetic bead accessories.

Applied BioCode Corporation was founded in 2016 and is based in Grand Cayman, the Cayman Islands.

Stock analysis

Applied BioCode (6598) currently trades at 27.00 TWD, while our model-based Fair Value estimate is 4.76 TWD, 82% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: 3.14 TWD (bear) to 5.94 TWD (bull), the price of 27.00 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Applied BioCode reported revenue of 475M TWD in FY2025 versus 320M TWD in FY2021, a compound +10.4%/yr. Reported net income was −201M TWD in FY2025.

Key figures

Market cap 2.8B TWD (≈ $84.6M) Micro · P/S ratio 4.49 · EPS (TTM) −0.4800 TWD · Net margin −7.3% · Return on equity −6.9% · Return on assets (EBIT) −18.9% (5-year average) · Operating margin 11.9% · Revenue (TTM) 667M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (medium confidence).

What moves the price

The share trades about 14% below its 52-week high and 31% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −82%, 6598 screens richer than that median.

Fair Value models

Bear 3.14 TWD Fair Value 4.76 TWD Bull 5.94 TWD
Price 27.00 TWD · Downside -82.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 3.14 TWD 4.76 TWD 5.94 TWD 55
All 1 models by family
Asset-Based
NCAV (Graham) 3.14 TWD 4.76 TWD 5.94 TWD 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 54/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 15
How much profit the company makes from its sales and capital
Quality Growth 74
Are margins and returns getting better?
Cashflow 14
Do the profits arrive as real cash?
Financial strength 99
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 70
How calm the share price moves, does not count
Price momentum 51
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 56
Distance to the 52-week high, does not count
New shares 46
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+38.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.7%
Start year 2020 (pandemic). Over 10 years: +35.2% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−33.2% (2020) → −47.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6598 screens overvalued: fair value 82% below the price. Compare with Abbott Laboratories, →

Compare Applied BioCode with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 54 · Above median
Fair Value upside −82.4% · Bottom 25%
Profitability
Return on assets −19.9% · Bottom 25%
Net margin (12 months) −7.3% · Below median
Operating margin (12 months) 11.9% · Above median
Growth and dividend
Revenue growth (quarter YoY) 81.3% · Top 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 4.32× · Priciest 25%
P/S (12 months) 4.17× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)100 · sector 35
PAST (return on equity)0 · sector 17
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs 6598
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs 6598
DexCom, Inc DXCM $79.41 $87.35 +10% vs 6598
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥197.22 +7% vs 6598
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs 6598
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs 6598
Siemens Healthineers AG SHL €44.66 €34.95 −22% vs 6598
Abbott Laboratories, ABT $109.93 $75.28 −32% vs 6598
Medtronic plc MDT $101.80 $65.61 −36% vs 6598
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs 6598

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Applied BioCode: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Applied BioCode Fair Value". https://www.fairvalue-calculator.com/stock/6598

Frequently asked questions

Is Applied BioCode (6598) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 4.76 TWD versus a price of 27.00 TWD, about 82% lower (overvalued).
What is the fair value of 6598?
Our model-based fair value for Applied BioCode is 4.76 TWD (as of Nov 9, 2026), built from audited fundamentals. The current price: 27.00 TWD.
What is the quality score of 6598?
Applied BioCode has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Applied BioCode (6598)?
Our model-based price target is the fair value of 4.76 TWD (as of Nov 9, 2026) from 1 valuation models. Cautious scenario 3.14 TWD, optimistic scenario 5.94 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Applied BioCode stock forecast for 2026?
Our models put fair value at 4.76 TWD, about 82% lower versus a price of 27.00 TWD (overvalued). Cautious scenario 3.14 TWD, optimistic scenario 5.94 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Applied BioCode (6598)?
Applied BioCode reported trailing-twelve-month revenue of about 667M TWD (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Applied BioCode (6598)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Applied BioCode it is 4.76 TWD per share (as of Nov 9, 2026), against a price of 27.00 TWD. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Applied BioCode stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 6598 trades above its calculated fair value: price 27.00 TWD, fair value 4.76 TWD, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6598?
No. The price is what the market pays today (27.00 TWD); the fair value is what the company's own numbers justify (4.76 TWD). For Applied BioCode the two are 22.24 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Applied BioCode worth?
The market values Applied BioCode at about 2.8B TWD (market capitalisation, as of Nov 9, 2026). Per share that is 27.00 TWD; our models calculate a fair value of 4.76 TWD per share.
What do the bullish and bearish scenarios say about 6598?
Our models span a range for Applied BioCode: cautious scenario 3.14 TWD, base 4.76 TWD, optimistic 5.94 TWD per share (as of Nov 9, 2026, price 27.00 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Applied BioCode (6598)?
Balance-sheet figures for Applied BioCode (as of Nov 9, 2026): return on equity −6.9%, debt of 0.01 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is 6598 from its 52-week high?
Applied BioCode trades at 27.00 TWD, about 14% below its 52-week high of 31.35 TWD and 31% above the low of 20.55 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 4.76 TWD is for.
Which stocks are comparable to Applied BioCode?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Applied BioCode stock attractive at the current price?
The data as of Nov 9, 2026: price 27.00 TWD, calculated fair value 4.76 TWD (−82%), Quality Score 54/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6598 calculated?
We run Applied BioCode through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 4.76 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Applied BioCode itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Applied BioCode (6598)?
The closing price on Nov 6, 2026 was 27.00 TWD. Our model-based fair value is 4.76 TWD, about 82% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Applied BioCode right now?
The price sits above even our optimistic bull case (5.94 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (3.14 TWD to 5.94 TWD) leaves room in how you read the outcome.

Key figures of Applied BioCode

How large is the market capitalisation of Applied BioCode (6598)?
The market capitalisation of Applied BioCode is 2.8B TWD (≈ $84.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Applied BioCode (6598)?
The price-to-sales ratio of Applied BioCode is 4.49 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Applied BioCode (6598)?
Earnings per share at Applied BioCode are −0.4800 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Applied BioCode (6598)?
The net margin of Applied BioCode is −7.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Applied BioCode (6598)?
The return on equity (ROE) of Applied BioCode is −6.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Applied BioCode (6598)?
On an EBIT basis the return on assets of Applied BioCode is −18.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Applied BioCode (6598)?
The operating margin of Applied BioCode is 11.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Applied BioCode (6598)?
Revenue at Applied BioCode is growing +81.3% versus a year earlier (3y avg +6.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Applied BioCode (6598) generate?
The free cash flow of Applied BioCode is −235M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Applied BioCode (6598) hold?
Applied BioCode holds more cash than debt, 405M TWD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Applied BioCode in the live analysis

One click puts Applied BioCode on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.